Should Prescription Drugs Become OTC? Two Experts Weigh In
In 2013, oxybutynin transdermal patches and triamcinolone acetonide nasal spray became OTC, followed by esomeprazole and fluticasone proprionate in 2014.1 FDA approval of Cialis (tadalafil) as OTC treatment for erectile dysfunction is currently being …
Read more on Monthly Prescribing Reference
Digital Tools Unveiled to Improve Doctor-Patient Interaction
For example, David Cerino, the company's CEO, explained that it might help a patient with prostate cancer evaluate the risk for erectile dysfunction or other adverse events against the increased longevity that a prostatectomy might provide. "At the …
Read more on Medscape
London, UK (PRWEB) June 19, 2014
Fine Treatment is pleased to share a new BPH treatment success story coming from Madrid, Spain. Charles O., 60, a user of Dr. Allens Device for Prostate Care, provided 2 feedback reports: the first one came after 3 months of using the device, and the second one was sent after the total treatment period of 6 months. In essence, the use of Dr. Allens Device has reduced enlarged prostate in size, gradually relieving the troubling BPH symptoms and markedly improving the quality of life.
On April 19, 2014, Fine Treatment received an email from Charles saying, Big thanks to Dr. Simon Allen for his wonderful device. I started to wear this device since January 14, 2014. Now, after 3 months, practically all the bad symptoms are gone. I only feel a little urgency to urinate. I enjoy my life again. I wish that all men would know about this device. Once more, thank you sir.
On June 10, 2014, Charles wrote, An ultrasound report, dated June 2, 2014, shows that the prostate size has become normal in comparison with the one from December 2013. It is really amazing. I sleep well all the night now, wakening up to urinate once or none.
Ill be happy to be interviewed by journalists and I can show them all my analyses and ultrasound report, adds Charles.
Fine Treatment works hard to disseminate treatment knowledge. Thermobalancing therapy is a superior treatment method enabled by Dr. Allens Devices. Fine Treatment does its best to make this natural treatment available internationally.
At the same time, recent articles in The Jewish Voice and Trinidad Express have reported issues with taking prostate medications, a common BPH treatment method which, however, is likely to cause nasty side effects.
The Jewish Voice article on Enlarged Prostate: What is it? What are the treatments? dated June 18, 2014, states: Alpha reductase inhibitors, Avodart or Proscar, reduce the size of the prostate, thus reducing the pressure on the urethra. Often, improvements are not seen for a couple of weeks or even months. Common side effects include decreased sex drive and erectile dysfunction.
Another article titled Doc, what to do about this BPH? in the Trinidad Express, of May 25, 2014, warns, It is important to note that one side effect of Alpha Blockers is they can lower your blood pressure causing dizziness that could lead to falls.
Fine Treatment is active in monitoring customer treatment progress. Here you can watch a short video: http://www.youtube.com/watch?v=V5xidswhxJM where a man has shrunk enlarged prostate by wearing Dr. Allens Device for 2 years without any medications.
Fine Treatments customer base stretches over 100 countries around the globe, notes Dr. Simon Allen. We do our best to help people to improve their health wherever they are. This new user report confirms the amazing effectiveness of therapeutic Dr. Allens Device and treatment method which cleanses the prostate gland and relieves nasty BPH symptoms naturally.
For details, visit Fine Treatment at http://finetreatment.com/bph-treatment-prostate-enlargement.
About Dr. Simon Allen and Fine Treatment:
Dr. Simon Allen, MD, PhD, Academician, member of the ATA, is a highly experienced medical professional. He specializes in internal medicine. He has treated a wide range of chronic diseases, including patients after a heart attack, with kidneys problems, including kidney stones disease, prostate and spine conditions, as well as metabolic disorders.
Fine Treatment supports global customer outreach, and ensures international availability of Dr. Allens Devices for the treatment of chronic prostatitis and BPH, coronary heart disease, for dissolving kidney stones, as well as for easing headaches, dizziness, and relieving lower back pain and sciatica.
Sex after prostate cancer
Despair is a common reaction, said Paul Nelson, a Hartford, Conn., teacher who became a clinical sexuality educator and founded the Erectile Dysfunction Foundation after surviving prostate cancer. "I tell them they're going to be OK, that they will …
Read more on Chicago Tribune
Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval
The drug, avanafil, can be effective when taken as early as 15 minutes before sexual activity, the company said. The U.S. Food and Drug Administration cleared the drug for marketing in its first approval of an erectile dysfunction treatment in nearly …
Read more on Benzinga
Albany, NY (PRWEB) March 03, 2014
According to a new market report published by Transparency Market Research “Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” the global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.
Browse the full report with complete TOC at http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options include lifestyle modification, testosterone therapy, penile devices, injection therapies and psychotherapy.
The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials.
In 2012, Viagra (sildenafil citrate) accounted for the largest share (45%) by revenue of the total erectile dysfunction drugs market. However, due to the loss of the drug’s patent exclusivity in Europe and other countries in 2013, the overall market revenue is expected to decline during the forecast period as international markets contribute considerably to the overall market revenue of the drug. In the U.S. market, Viagra will continue to maintain a major revenue share due to its extended patent exclusivity till 2020. The market for Cialis (tadalafil) accounted for the second largest share at USD 1,926.8 million, in 2012. However, it is expected to witness a decline in market revenue at a CAGR of (12.6%) from 2013 to 2019, owing to loss of patent exclusivity in 2017. In addition, the patent for Bayer’s Levitra/Staxyn (vardenafil) is scheduled to expire in 2018 and is thus expected to contribute to the declining market revenue.
A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.
Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer’s Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.
Related Report: Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market
This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva. Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and few others have also been included in the report. Market size and forecasts for the period 2010 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 – 2019 has also been provided along with market size estimations.
Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The respective market size and forecast till 2019 for each region has also been presented in the report along with the CAGR. In addition, the market overview section of the report provides a qualitative assessment of the market dynamics wherein the drivers, restraints, and opportunities along with market attractiveness and Porters Five Forces analysis have been studied.
Browse Blog: http://www.tmrblog.com/
Browse all Market Research reports: http://www.transparencymarketresearch.com
Belly lint, WiFi and hamsters on Viagra – inside the Ig Nobel prizes
Look down at your bellybutton – discreetly, if you're at work. Is there fluff or lint inside it? Yes? There's a very strong chance that it's blue. The reasons for this only became clear when Australian scientist, author and broadcaster Dr Karl …
Read more on ninemsn
Man jailed for peddling hyper-strength 'herbal' erection tablets
A man has been sentenced to 16 weeks in a UK prison for selling sham 'Herbal Viagra' tablets that contained dangerous levels of tadalafil and sibutramine, compounds that are banned in supplements.
Read more on NutraIngredients.com
Welch Allyn adds early warning scoring to Connex Vital Signs Monitor at no …
Aston Abbotts, UK – (HealthTech Wire / News) – Welch Allyn is now supporting the drive to improve patient safety and buy viagra lowest price reduce error rates with the addition of electronic Early Warning Score (EWS) functionality to its Connex® Vital …
Read more on HealthTech Wire
Boston, MA (PRWEB) August 05, 2014
Every day, about half of American adults take a vitamin, mineral, herb, amino acid, or other dietary supplement. Most do this because they seek to improve or maintain their health. Others do it in hopes of staving off heart disease. Yet only a handful of supplements offer possiblethough limitedhelp against heart disease. Some popular ones have no benefit, and others contain dangerous contaminants, reports the August 2014 Harvard Heart Letter.
“A lot of people want to add something natural and alternative to the conventional medications they’re taking, and they assume that dietary supplements might help and can’t hurt,” says Dr. Pieter Cohen, a dietary supplement safety researcher and assistant professor of medicine at Harvard Medical School. But that’s not the case.
Unlike pharmaceuticals, which undergo extensive testing to prove they’re effective and safe before they can be sold, dietary supplements can be sold without proof of effectiveness or safety. Moreover, supplement makers can claim their products improve health, even when there’s little or no evidence to support such claims.
Multivitamins are one of the most popular supplements taken by people trying to prevent heart disease. But large, “gold standard” trials have shown that taking a daily multivitamin does not ward off heart disease. Small studies suggest that some dietary supplements, such as red yeast rice, lowers cholesterol, a risk factor for heart disease. Yet the amount of the active ingredient in red yeast rice products varies widely, from very low to very high. And up to one-third of red rice yeasts products may be contaminated with a kidney toxin called citrinin.
Such contamination isn’t rare. As Dr. Cohen noted in a perspective in The New England Journal of Medicine, the FDA has found more than 500 supplements adulterated with pharmaceuticals or closely related compounds. The offenders include stimulants, body-building steroids, antidepressants, weight-loss medications, and supplements aimed at treating erectile dysfunction. All can cause unwanted side effects and may be especially risky when taken with heart drugs or other prescription medications.
Because of the potential risks and unclear benefits of dietary supplements, most doctors advise their patients to avoid them, though they may recommend specific supplements such as calcium and vitamin D to prevent osteoporosis.
For most people, “a well-balanced diet rich in whole foods including fruits, vegetables, fish, olive oil, and nuts negates the need for any supplements,” says Dr. Cohen.
Read the full-length article:”Dietary supplements: Sorting out the science”
Also in the August 2014 issue of the Harvard Heart Letter:
Chesco drugmaker Auxilium announces staff cuts
Auxilium Pharmaceuticals Inc., a Chesterbrook-based drugmaker that sells testosterone-replacement and other treatments for men with erectile-dysfunction issues, says it has cut 30 percent of its staff and consolidated its three sales forces into two.
Read more on Philly.com
Testosterone: What You Need To Know About The Most Important Male Sex …
Signs and symptoms may include: erectile dysfunction, decreased sexual desire, fatigue and loss of energy, depression, loss of certain male physical characteristics and osteoporosis.3,4 However, the effects of low testosterone needn't be a permanent …
Read more on Bloomer Advance (subscription)
Suspect Small Fiber Neuropathies for Unexplained Neuropathic Pain
LAS VEGAS—Recognizing the existence of small fiber neuropathies (SFNs) and their association with more conditions than previously identified may lead to improved treatment approaches, said Charles E. Argoff, MD, Professor of Neurology, Albany Medical …
Read more on Monthly Prescribing Reference
What You Need to Know About Prostate Cancer–From Dr. Drew
Dr. Drew Pinsky returned from a Caribbean vacation two years ago feeling ill, with chills so rattling that he had to go to the hospital. He figured he must have caught a tropical disease. Although his symptoms passed, his wife urged him to get a follow …
Read more on Forbes
Wellness: Adrenal glands control hormones
The symptoms of Cushing's disease can include weight gain, stretch marks, fitting and fragile skin, slow healing of cuts and infections, acne, and in men a decreased libido, decreased fertility and erectile dysfunction. Symptoms can include … liver …
Read more on The News-Press
Study: Testosterone Replacement Ineffective in Men with Type 2 Diabetes
There was no significant difference between the beginning and end of the study in erectile function in either group. Researchers concluded that in this trial, “testosterone treatment did not substantially improve constitutional or sexual symptoms in …
Read more on Legal Examiner
Burden of Proof
With the eyes of the world on Ferguson, Missouri, our collective attention is focused on the different treatment of black and white people at the hands of America's criminal justice system. The focus is well deserved. More than 50 years after the Civil …
Read more on Vox
The Silent Treatment: Studies Reveal 'Tremendous Damage' To Relationships
Not only does the demand-withdraw pattern have emotional effects on both partners, but it can also have physiological effects that are frequently the result of anxiety and aggressive behavior. Physical manifestations include problems with erectile …
Read more on Beliefnet
Methadone Brings Down Testosterone Levels In Opioid Addicts
The study found that men on methadone treatment had testosterone levels one-fourth lower than those of men who were not taking opioids. Low testosterone levels leads to poor quality of life, erectile dysfunction, fatigue and instability of mood in men.
Read more on International Business Times AU
Urologists Schenkman and Raspa join Crystal Run
Schenkman, Raspa and Lopez provide care for enlarged prostate, erectile dysfunction, incontinence, frequent infections and offer leading-edge treatments for prostate cancer. Schenkman is board-certified in urology. He received his Medical Degree from …
Read more on Times Herald-Record
Mae West Knew When Men Were Men
As a male, have you lost the “tiger-in-the-tank”? Possibly you are more irritable, suffer insomnia, have problems at work, lost height, lack energy and lack erections? Now you wonder if testosterone therapy is what's needed to restore your male vigour?
Read more on Canada Free Press